We sat down with Julie Kennerly-Shah, PharmD, assistant director of Pharmacy at the Ohio State University Comprehensive Cancer Center-James Cancer Hospital and Solove Research Institute to discuss cost cutting with biosimilars.
As summer fades away and the United States prepares for a potential second wave of coronavirus disease 2019 (COVID-19) cases, many are worried that economic impacts and rising health care costs will continue unless action is taken. Europe’s competitive biosimilar market has proven that biosimilars have the potential to lower costs. But with existing barriers, such as lack of education and payer oversight of formularies, and the continuing pandemic, there is some debate on whether biosimilars will have the same impact in the United States.
We sat down with Julie Kennerly-Shah, PharmD, assistant director of Pharmacy at the Ohio State University Comprehensive Cancer Center-James Cancer Hospital and Solove Research Institute to discuss how biosimilars can help curb costs in the time of COVID-19 and beyond.
To learn more about COVID-19's impact on biosimilars, click here.
To learn more about biosimilar education, click here.
To learn more about step therapy, click here.
To learn more about payer interference on preferred drugs, click here.
Biosimilars Gastroenterology Roundup for February 2023—Podcast Edition
March 5th 2023On this episode of Not So Different, we chronicle the latest gastroenterology news from February, including several updates on adalimumab and infliximab biosimilars and industry analyses on the utilization of these drugs and patient confidence in gastroenterologists’ recommendations.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
AAM's Craig Burton: Is the Biden Administration Doing Enough to Help Biosimilars?
November 13th 2022Craig Burton, senior vice president of policy and strategic alliances at the Association for Accessible Medicines and executive director of the Biosimilars Council, gives insight into the many health policies that the Biden administration has implemented in 2022 as well as their possible impact on biosimilar adoption.
How Health Policy Can Impact Adoption for Adalimumab Biosimilars
September 25th 2022In this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, discussed current policy initiatives that could help biosimilar adoption and how the Inflation Reduction Act is expected to influence the adalimumab market.